156 results
SC TO-T/A
EX-99
INHX
Inhibitex, Inc.
19 Jan 12
Third party tender offer statement (amended)
12:00am
on the development of anti-infection drugs to prevent or treat serious infections. It primarily focuses on products to treat shingles and chronic infections … . Inhibitex’s primary pipeline drug is INX-189, which is currently undergoing clinical trials. INX-189 is developed to treat chronic infections caused
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
24 Jan 14
Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2013 Financial Results
12:00am
validated the company’s marketing authorization application for daclatasvir, an investigational NS5A complex inhibitor, to treat adults with chronic hepatitis … agents, including sofosbuvir, to treat chronic hepatitis C. The validation marks the start of an accelerated regulatory review process for daclatasvir
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
27 Jan 11
Receives U.S. Regulatory Approval for KOMBIGLYZE™ XR, and First-Line Indication for SPRYCEL® in Fourth Quarter
12:00am
.
In October, the FDA approved SPRYCEL 100 mg once daily for newly diagnosed adults with Philadelphia chromosome-positive chronic phase chronic myeloid … .
In October, the FDA approved the supplemental New Drug Application (sNDA) of BARACLUDE for the treatment of chronic hepatitis B in adult patients
SC TO-T/A
EX-99
BMY
Bristol-Myers Squibb Co.
17 Nov 20
Third party tender offer statement (amended)
8:33am
medicine for the treatment of obstructive hypertrophic cardiomyopathy (“HCM”), a chronic heart disease with high morbidity and patient impact. A New Drug … offer, toll free, at 1-800-322-2885.
About Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is a chronic, progressive disease
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
27 Oct 15
Bristol-Myers Squibb Reports Third Quarter Financial Results
12:00am
labeling to include five-year efficacy and safety data in adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid … leukemia (CML) in chronic phase (CP) and seven-year data in the same patient population who are resistant or intolerant to prior therapy, including imatinib
8-K
EX-99.1
ivoa3 6lqd843
22 Jul 10
Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data
12:00am
SC TO-C
EX-99.4
h3mrlb5wbtly4b3fuij
5 Oct 20
Information about tender offer
5:13pm
8-K
EX-99.1
kfbgti4ghr5enh7p
24 Apr 08
Strong Double-digit Net Sales Growth and Solid Earnings Growth
12:00am
8-K
EX-99.1
thy03b3se0g du
5 Oct 20
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
4:05pm
SC TO-C
EX-99.1
wz6u tl37mzkoyzcj
5 Oct 20
Information about tender offer
5:13pm
8-K
EX-99.1
4xi s79gp2sf95je
26 Oct 10
Robust Clinical Data and the Strategic Acquisition of ZymoGenetics
12:00am
8-K
EX-99.1
ju5qi q8kpc8r2u
9 Jan 12
Bristol-Myers Squibb to Acquire Inhibitex
12:00am
8-K
EX-99.1
ch3a51h
28 Jul 11
Important Clinical Data and Strong Financial Results
12:00am
8-K
EX-99.1
cq3 not5ch
7 Aug 08
Completion of Convatec Divestiture
12:00am
SC TO-T
EX-99
dt0iy5
13 Jan 12
Third party tender offer statement
12:00am
8-K
EX-99.1
su3m7 m0s
25 Apr 13
Bristol-Myers Squibb Reports First Quarter 2013 Financial Results
12:00am